title: Periprocedural management of antithrombotic therapy and open issues in cancer patients.
abstract: Perioperative management of patients who are receiving anticoagulant or antiplatelet drugs and require surgical or invasive procedure is a dilemma for clinicians. The discontinuation exposes the patient to an exceedingly high risk of thromboembolism while there is an exceedingly high bleeding risk if antithrombotic therapy is continued, strictly related to the type of surgery. This complex management is based on the assessment of thromboembolic and bleeding risk. In this review we analyze the strategies to optimize the perioperative use of antithrombotic drugs with special attention to new oral anticoagulant drugs, also in cancer patients.
authors: Division of Anesthesia, Intensive Care and Pain Therapy Unit, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy - a.cuomo@istitutotumori.na.it.
authors: A
authors: A
authors: Cuomo
authors: M
authors: M
authors: Cascella
authors: F
authors: F
authors: Bifulco
authors: M
authors: M
authors: Marracino
authors: G
authors: G
authors: Di Minno
authors: A
authors: A
authors: Cerbone
mesh_terms: D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D019990:Perioperative Care / Q000009:adverse effects / Q000379:methods; D013923:Thromboembolism / Q000517:prevention & control
chemical_list: D005343:Fibrinolytic Agents